Patents Assigned to ANTECIP BIOVENTURES II LLC
  • Bupropion as a modulator of drug activity
    Patent number: 11123343
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: October 5, 2020
    Date of Patent: September 21, 2021
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Bupropion as a modulator of drug activity
    Patent number: 11096937
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: October 20, 2020
    Date of Patent: August 24, 2021
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Bupropion as a modulator of drug activity
    Patent number: 11090300
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: March 18, 2020
    Date of Patent: August 17, 2021
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Bupropion as a modulator of drug activity
    Patent number: 11065248
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: September 23, 2020
    Date of Patent: July 20, 2021
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Bupropion as a modulator of drug activity
    Patent number: 11058648
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: November 16, 2020
    Date of Patent: July 13, 2021
    Assignee: Antecip Bioventures II LLC
    Inventor: Herriot Tabuteau
  • Bupropion as a modulator of drug activity
    Patent number: 11020389
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: October 1, 2020
    Date of Patent: June 1, 2021
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Bupropion as a modulator of drug activity
    Patent number: 11007189
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: March 23, 2020
    Date of Patent: May 18, 2021
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Bupropion as a modulator of drug activity
    Patent number: 10980800
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: October 12, 2020
    Date of Patent: April 20, 2021
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Bupropion as a modulator of drug activity
    Patent number: 10966942
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: September 18, 2020
    Date of Patent: April 6, 2021
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Bupropion as a modulator of drug activity
    Patent number: 10966974
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: March 18, 2020
    Date of Patent: April 6, 2021
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Bupropion as a modulator of drug activity
    Patent number: 10945973
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: August 3, 2020
    Date of Patent: March 16, 2021
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Bupropion as a modulator of drug activity
    Patent number: 10940124
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: September 16, 2020
    Date of Patent: March 9, 2021
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Bupropion as a modulator of drug activity
    Patent number: 10933034
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: August 26, 2020
    Date of Patent: March 2, 2021
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Bupropion as a modulator of drug activity
    Patent number: 10925842
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: February 23, 2021
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Bupropion as a modulator of drug activity
    Patent number: 10898453
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: January 26, 2021
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Bupropion as a modulator of drug activity
    Patent number: 10894046
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: March 17, 2020
    Date of Patent: January 19, 2021
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Bupropion as a modulator of drug activity
    Patent number: 10894047
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: January 19, 2021
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Bupropion as a modulator of drug activity
    Patent number: 10881657
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: January 5, 2021
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
    Patent number: 10881624
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: September 12, 2018
    Date of Patent: January 5, 2021
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Bupropion as a modulator of drug activity
    Patent number: 10874664
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: March 19, 2020
    Date of Patent: December 29, 2020
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau